MedPageToday -- Even after patients stopped taking the painkiller rofecoxib (Vioxx) when it was pulled from the market, their risk of cardiovascular events remained high, researchers reported.
MedPageToday -- Even after patients stopped taking the painkiller rofecoxib (Vioxx) when it was pulled from the market, their risk of cardiovascular events remained high, researchers reported.
